FIRST Fund: PHLOX THERAPEUTICS CLOSES SEED INVESTMENT ROUND
16 May 2020, Naarden, The Netherlands - Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as its initiating director of operations have announced the...
BGV Fellowship
Location: Naarden, The Netherlands Duration: 6-9 months About BGV Since our inception in 2006, BGV has raised four early-stage biotech funds totaling over €250 million in capital. Our portfolio is focused on novel therapeutics across different treatment modalities and...
Scenic Biotech and the Barth Syndrome Foundation Announce
Partnership to Explore Genetic Modifiers to a Find Tailored
Treatment for the Complex Rare Disease
Amsterdam, The Netherlands, and Boston, MA, USA - 30 March 2022 - Scenic Biotech BV (‘Scenic’ or ‘the Company’), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other...
Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease
- Second Orphan Drug Designation Supports Azafaros’ Strategy to Develop AZ-3102 as a Disease Modifying Treatment in a Range of Severe Rare Inherited Metabolic Disorders – Leiden, The Netherlands, March 24, 2022 – Azafaros B.V. today announced that the US Food and Drug...
Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain
Ghent, Belgium – March 10, 2022 - Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical...
Scenic Biotech Announces $31 Million Financing to Progress
Pipeline of Genetic Modifiers in Cancer and Rare Diseases
Amsterdam, The Netherlands, 10 March 2022 - Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, is pleased to announce it...
NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD)
01 March 2022 - NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases, today announced dose administration for the first patient in its PREVAIL study, a global Phase 3...
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
Munich, Germany, March 1, 2022 – CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy of the company’s lead product...
Forbion and BGV announce EUR 5 million seed investment in Complement Therapeutics and appointment of Dr Rafiq Hasan as CEO
Naarden, The Netherlands - 23 February 2022 - Forbion and BioGeneration Ventures (BGV), two leading European life sciences venture capital firms, today announce the completion of a EUR 5 million Series Seed financing round in Complement Therapeutics Ltd (CTx), a...
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients
Utrecht, the Netherlands, 22 February 2022 - TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today announces it has raised Series A financing of EUR 39 million to accelerate...